CRVO: Phase III-ready DLB therapy advances with new formulation and global regulatory alignment

Major advances were made in the clinical development of neflamapimod for dementia with Lewy bodies, including replicated phase 2 results, regulatory alignment on endpoints, and resolution of formulation issues. A phase III trial is planned with a new stable formulation and global regulatory support…Read More